Breakthrough
First-in-Human Study: Inhaled Stem Cell Vesicles for Pulmonary Fibrosis
A Phase I trial published by a Tsinghua University team reported the safety and early findings of nebulized stem cell-derived extracellular vesicles.
Published in the Nature family · Peer-reviewed research
Stem Cell Exosome Nebulization Repair Damaged Lungs. Breathe Freely Again.
The world's first Japanese-patented stem cell exosome therapy you simply inhale
PIC/S GMP manufactured · Needle-free · Targeted repair
Japanese Patent
PIC/S GMP
SGS Tested
Peer-Reviewed
Nature Communications
Backed by Peer-Reviewed Science
The figures below are cited from research published in a Nature-family journal by an independent research team. We have no affiliation, partnership, sponsorship or endorsement relationship with the researchers or their institutions.
24 Patients
A randomized, double-blind, placebo-controlled Phase II trial.
FVC +12.5%
Forced vital capacity rose significantly (p < 0.01).
6MWD +45 m
Six-minute walk distance improved meaningfully.
Zero Adverse Events
No serious treatment-related reactions were observed.
What Sets JuvGuard Apart
Six strengths behind a safer, more effective approach to lung repair.
Japanese Patent
Granted a patent by the Japan Patent Office — the core technology is protected worldwide.
PIC/S GMP Manufacturing
Produced to international pharmaceutical GMP standards, so every batch performs identically.
Targeted Repair
Exosomes home in on damaged lung tissue, reaching precisely where repair is needed.
Needle-Free Inhalation
Simply breathe it in. No injections — suitable for the clinic or the comfort of home.
450+ Bioactive Factors
Loaded with growth factors, miRNA and proteins that work together across multiple targets.
Published Literature Reference
Development has been informed by exosome research published in the peer-reviewed literature.
A Four-Stage Mechanism
Multiple targets working in concert to repair lung damage.
01
Targeted Delivery
Its miRNA and protein cargo seeks out and binds injured alveolar and fibroblast cells.
02
Calming Inflammation
Dials down IL-6 and TNF-α while lifting IL-10, restoring immune balance in the lung.
03
Tissue Regeneration
Growth factors drive alveolar cells to multiply and rebuild the damaged tissue.
04
Reversing Fibrosis
Suppresses the TGF-β/Smad pathway, cutting collagen build-up and rolling back fibrosis.
Cases That Show the Difference
Real-world outcomes from exosome nebulization therapy.
Pulmonary Fibrosis
12 Weeks
Male, 65 · IPF
FVC: 58% → 71%
Breathlessness eased markedly after 12 weeks, with HRCT showing a reduced fibrosis burden.
Lung Nodules
24 Weeks
Male, 67
Nodule: 12 mm → resolved
A 12 mm mixed ground-glass nodule in the right upper lobe fully resolved on CT at week 24.
White Lung
8 Weeks
Female, 52 · post-COVID
FVC: 58% → 72%
Post-COVID fibrosis in both lungs recovered substantially after 8 weeks of treatment.
COPD
16 Weeks
Male, 72 · COPD
FEV1: 45% → 58%
A long-standing COPD patient gained lung function and suffered far fewer flare-ups.
Research & Industry Partners
IQ GENETIC TECHNOLOGY LIMITED
HKRM
PIC/S GMP
The Latest in Exosome Research
Keeping you close to the frontier of exosome medicine.
Clinical Insight
Nebulized Exosomes in the Management of Lung Nodules
Follow-up data shows measurable shrinkage in nodule size among patients receiving nebulized therapy.
Explainer
How Do Exosomes Rebuild Lung Tissue?
Starting with a 30–150 nm vesicle, we unpack how exosomes carry signals that orchestrate repair.
Ready to Take the Next Step?
Speak with a JuvGuard sales consultant to find out whether it is right for you.
No-obligation consultation
Tailored recommendations
One-to-one support
To purchase, contact a sales consultant
WhatsApp & phone: +852 6746 9492
Anything you share stays strictly confidential.